<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945644</url>
  </required_header>
  <id_info>
    <org_study_id>16025-H17</org_study_id>
    <nct_id>NCT02945644</nct_id>
  </id_info>
  <brief_title>Trazodone Dose Tolerance and APAP Adherence</brief_title>
  <acronym>TrazoDose</acronym>
  <official_title>Randomized Controlled Trial of Trazodone Dose Tolerance and APAP Adherence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louis Stokes VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Louis Stokes VA Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trazodone may help obstructive sleep apnea patients to stick to their therapy, but optimal&#xD;
      dosing is unknown. This study looks at what dose of trazodone has the best balance of&#xD;
      potential benefits to side-effects in people with obstructive sleep apnea who are either&#xD;
      starting on positive airway pressure therapy or not adherent to it. Participants will be&#xD;
      randomly assigned to one of three groups: trazodone 50 mg, trazodone 100 mg, or placebo for&#xD;
      14 days. The investigators will monitor side-effects and adherence to positive airway&#xD;
      pressure therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical Significance: Trazodone is an often-used medication in clinical sleep medicine.&#xD;
      However, there is a dearth of information on side-effects with doses typically used for&#xD;
      sleep. In addition, a significant proportion of the VA population have obstructive sleep&#xD;
      apnea for which the primary treatment is positive airway therapy. However, many patients have&#xD;
      difficulty adhering to this treatment long-term. Increased adherence to this modality has&#xD;
      been shown to improve risk for cardiovascular and neurologic co-morbidity associated with&#xD;
      obstructive sleep apnea. This project explores both the tolerability and safety of common&#xD;
      doses of trazodone used in clinical sleep practice as well explores potential effects on&#xD;
      positive airway pressure therapy adherence.&#xD;
&#xD;
      Objectives: This project seeks to determine the tolerability and multi-domain effect on sleep&#xD;
      and mood of a 14 day course of trazodone at either 50 mg or 100 mg or placebo.&#xD;
&#xD;
      Research Plan: This is a three-group, randomized, double-blind, placebo-controlled trial with&#xD;
      prospective data collection of VA outpatient sleep clinic patients with obstructive sleep&#xD;
      apnea with who are non-adherent or newly started on auto-titrating positive airway pressure&#xD;
      therapy. Evaluation focuses on medication tolerability as measured by number of days before&#xD;
      study drug discontinuation by the participant, the Treatment Satisfaction Questionnaire for&#xD;
      Medication, the side-effect profile at the two doses (50mg and 100mg) compared to placebo as&#xD;
      well as longitudinal collection of adherence data and standardized questionnaires on&#xD;
      sleepiness, insomnia, depression, anxiety, and self-efficacy. The investigators also plan to&#xD;
      longitudinally monitor coefficient of variation of breath-to-breath tidal volume, a measure&#xD;
      of respiratory mechanics which may be affected by trazodone use. Study participants will have&#xD;
      2 visits at baseline and 2 weeks after randomization.&#xD;
&#xD;
      Methodology: This study will be conduced in the Louis Stokes Cleveland Medical Center - Wade&#xD;
      Park Sleep Clinic, a tertiary institutional referral facility. Participants must be adults&#xD;
      with obstructive sleep apnea prescribed auto-titrating positive airway therapy who are either&#xD;
      newly initiated or do not fulfill standard criteria for adherence and do not have allergy to&#xD;
      trazodone; current use of trazodone, monoamine oxidase inhibitors, or sedative hypnotics;&#xD;
      alcohol or drug abuse; severe psychiatric disease; epilepsy; significant cardiac disease;&#xD;
      liver disease; pregnancy; hypotension; or predisposition to priapism. Study staff will&#xD;
      interview the potential participant and do a review of the medical record for exclusion&#xD;
      criteria before consent is obtained. The investigators expect to recruit 45 participants into&#xD;
      the study with a 20% attrition rate before completion. Hypothesis about the tolerability of&#xD;
      trazodone and effect on positive airway therapy adherence was prespecified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID19 pandemic&#xD;
  </why_stopped>
  <start_date type="Actual">February 13, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Discontinuation rate by participant</measure>
    <time_frame>14-16 days post-randomization</time_frame>
    <description>Did the participant discontinue trazodone at a higher rate than placebo?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 month APAP adherence</measure>
    <time_frame>3 months post-randomization assessing 30 days before this 3 month period</time_frame>
    <description>APAP use in last 30 days (of the 3 month period) as measured by (1) average hours/day and (2) percent days with 4 or more hours use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory patterning</measure>
    <time_frame>14-16 days post-randomization</time_frame>
    <description>Variation of breath to breath tidal volume obtained from plethysmography (a stretchy band around the chest x 20 minutes while wearing APAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Satisfaction</measure>
    <time_frame>14-16 days post-randomization</time_frame>
    <description>Treatment Satisfaction Questionnaire for Medications version II overall and subscale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side-effect profile</measure>
    <time_frame>14-16 days post-randomization</time_frame>
    <description>participant-reported side effects of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleepiness</measure>
    <time_frame>14-16 days post-randomization</time_frame>
    <description>Epworth Sleepiness Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insomnia</measure>
    <time_frame>14-16 days post-randomization</time_frame>
    <description>Insomnia Severity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>general self-efficacy</measure>
    <time_frame>14-16 days post-randomization</time_frame>
    <description>General Self-Efficacy Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>depression</measure>
    <time_frame>14-16 days post-randomization</time_frame>
    <description>Clinically Useful Depression Outcome Scale (CUDOS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anxiety</measure>
    <time_frame>14-16 days post-randomization</time_frame>
    <description>Clinically Useful Anxiety Outcome Scale (CUXOS)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>pill filled with inert material</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trazodone 50mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trazodone 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone</intervention_name>
    <description>take at bedtime for 14 days</description>
    <arm_group_label>Trazodone 100mg</arm_group_label>
    <arm_group_label>Trazodone 50mg</arm_group_label>
    <other_name>oleptro</other_name>
    <other_name>Desyrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>take at bedtime for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Louis Stokes Cleveland VA Sleep Medicine clinic patient&#xD;
&#xD;
          -  AHI greater than or equal to 5&#xD;
&#xD;
          -  obstructive sleep apnea&#xD;
&#xD;
          -  new initiation or nonadherence to APAP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  schizophrenia&#xD;
&#xD;
          -  bipolar disorder&#xD;
&#xD;
          -  current use of trazodone or sedative hypnotics&#xD;
&#xD;
          -  allergy to trazodone&#xD;
&#xD;
          -  current use of tricyclic antidepressants or monoamine oxidase inhibitors&#xD;
&#xD;
          -  current alcohol or drug abuse&#xD;
&#xD;
          -  heart failure&#xD;
&#xD;
          -  heart attack in past 3 months&#xD;
&#xD;
          -  congenital long QT, ventricular arrhythmia (including Torsades de Pointes),&#xD;
             bradycardia, or digoxin therapy&#xD;
&#xD;
          -  use of amiodarone, sotalol, dofetilide, or dronedarone&#xD;
&#xD;
          -  epilepsy&#xD;
&#xD;
          -  liver disease&#xD;
&#xD;
          -  pregnancy (or planning pregnancy)&#xD;
&#xD;
          -  right of priapism: history of priapism, sickle cell disease, Farby disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kingman P Strohl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louis Stokes Cleveland VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Louis Stokes Cleveland VA Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Louis Stokes VA Medical Center</investigator_affiliation>
    <investigator_full_name>Kingman Strohl</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>trazodone</keyword>
  <keyword>positive airway pressure</keyword>
  <keyword>adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

